Top

Published in:

01-04-2019 | Review

WWP2 Is One Promising Novel Oncogene

Authors: Rui Zhang, Jianwu Zhang, Wei Luo, Zhuang Luo, Shaoqing Shi

Published in: Pathology & Oncology Research | Issue 2/2019

Abstract

WWP2 is an E3 ubiquitin ligase and plays an important role in regulation of many cellular biological activities through ubiquitination and degradation of its substrates. Recently accumulating evidences indicate that WWP2 plays a crucial part in the pathogenesis in different types of tumors. In this report, the role of this gene especially in tumorigenesis was reviewed. WWP2 is dysregulated in various of tumors, and it promotes carcinogenesis mainly through PTEN/Akt signaling pathway. WWP2 also participates in anti-cancer agents’ sensitivity, indicating WWP2 may be a novel target for cancer treatment. WWP2 is one promising novel oncogene.

Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, Chanda SK, Batalov S, Joazeiro CA (2008) Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 3:e1487CrossRefPubMedPubMedCentral

Bernassola F, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14:10–21CrossRefPubMed

Lu PJ, Zhou XZ, Shen M, Lu KP (1999) Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283:1325–1328CrossRefPubMed

Pirozzi G, McConnell SJ, Uveges AJ, Carter JM, Sparks AB, Kay BK, Fowlkes DM (1997) Identification of novel human WW domain-containing proteins by cloning of ligand targets. J Biol Chem 272:14611–14616CrossRefPubMed

Wood JD, Yuan J, Margolis RL, Colomer V, Duan K, Kushi J, Kaminsky Z, Kleiderlein JJ, Sharp AH, Ross CA (1998) Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci 11:149–160CrossRefPubMed

Xu H, Wang W, Li C, Yu H, Yang A, Wang B, Jin Y (2009) WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. Cell Res 19:561–573CrossRefPubMed

Soond SM, Chantry A (2011) Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFbeta signalling and EMT. Oncogene 30:2451–2462CrossRefPubMedPubMedCentral

Liao B, Jin Y (2010) Wwp2 mediates Oct4 ubiquitination and its own auto-ubiquitination in a dosage-dependent manner. Cell Res 20:332–344CrossRefPubMed

Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM, Jin Y (2004) Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem 279:23495–23503CrossRefPubMed

10.

McDonald FJ, Western AH, McNeil JD, Thomas BC, Olson DR, Snyder PM (2002) Ubiquitin-protein ligase WWP2 binds to and downregulates the epithelial Na(+) channel. Am J Physiol Renal Physiol 283:F431–F436CrossRefPubMed

11.

Li H, Zhang Z, Wang B, Zhang J, Zhao Y, Jin Y (2007) Wwp2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells. Mol Cell Biol 27:5296–5305CrossRefPubMedPubMedCentral

12.

Luo X, Wang B, Tang F, Zhang J, Zhao Y, Li H, Jin Y (2014) Wwp2 targets SRG3, a scaffold protein of the SWI/SNF-like BAF complex, for ubiquitination and degradation. Biochem Biophys Res Commun 443:1048–1053CrossRefPubMed

13.

Yang Y, Liao B, Wang S, Yan B, Jin Y, Shu HB, Wang YY (2013) E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation. Proc Natl Acad Sci U S A 110:5115–5120CrossRefPubMedPubMedCentral

14.

Lv Y, Zhang K, Gao H (2014) Paip1, an effective stimulator of translation initiation, is targeted by WWP2 for ubiquitination and degradation. Mol Cell Biol 34:4513–4522CrossRefPubMedPubMedCentral

15.

Chen A, Gao B, Zhang J, McEwen T, Ye SQ, Zhang D, Fang D (2009) The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Mol Cell Biol 29:5348–5356CrossRefPubMedPubMedCentral

16.

Chen W, Jiang X, Luo Z (2014) WWP2: a multifunctional ubiquitin ligase gene. Pathol Oncol Res 20:799–803CrossRefPubMed

17.

Chantry A (2011) WWP2 ubiquitin ligase and its isoforms: new biological insight and promising disease targets. Cell Cycle 10:2437–2439CrossRefPubMedPubMedCentral

18.

Choi BH, Che X, Chen C, Lu L, Dai W (2015) WWP2 is required for normal cell cycle progression. Genes cancer 6:371–377PubMedPubMedCentral

19.

Clements AE, Bravo V, Koivisto C, Cohn DE, Leone G (2015) WWP2 and its association with PTEN in endometrial cancer. Gynecol Oncol Rep 13:26–29CrossRefPubMedPubMedCentral

20.

Fukumoto C, Nakashima D, Kasamatsu A, Unozawa M, Shida-Sakazume T, Higo M, Ogawara K, Yokoe H, Shiiba M, Tanzawa H, Uzawa K (2014) WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice. Oncoscience 1:807–820CrossRefPubMedPubMedCentral

21.

Liang J, Qi WF, Xie S, Wang WF, Zhang XL, Zhou XP, Hu JX, Yu RT (2017) Expression of WW domain-containing protein 2 is correlated with pathological grade and recurrence of glioma. J Cancer Res Ther 13:1032–1037PubMed

22.

Soond SM, Smith PG, Wahl L, Swingler TE, Clark IM, Hemmings AM, Chantry A (2013) Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer. Biochim Biophys Acta 1832:2127–2135CrossRefPubMed

23.

Xu SQ, Qin Y, Pan DB, Ye GX, Wu CJ, Wang S, Jiang JY, Fu J, Wang CJ (2016) Inhibition of WWP2 suppresses proliferation, and induces G1 cell cycle arrest and apoptosis in liver cancer cells. Mol Med Rep 13:2261–2266CrossRefPubMed

24.

Yang R, He Y, Chen S, Lu X, Huang C, Zhang G (2016) Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion. Biochem Biophys Res Commun 479:146–151CrossRefPubMed

25.

Jung JG, Stoeck A, Guan B, Wu RC, Zhu H, Blackshaw S, Shih Ie M, Wang TL (2014) Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genet 10:e1004751CrossRefPubMedPubMedCentral

26.

Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, Chen J (2011) WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 13:728–733CrossRefPubMedPubMedCentral

27.

Qin Y, Xu SQ, Pan DB, Ye GX, Wu CJ, Wang S, Wang CJ, Jiang JY, Fu J (2016) Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells. Tumour Biol 37:6787–6799CrossRefPubMed

28.

Yu Z, Li T, Wang C, Deng S, Zhang B, Huo X, Wang X, Zhong Y, Ma X (2016) Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells. Oncotarget 7:15725–15737PubMedPubMedCentral

29.

Ding ZY, Huang YJ, Tang JD, Li G, Jiang PQ, Wu HT (2016) Silencing of hypoxia-inducible factor-1alpha promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2. Exp Ther Med 12:3735–3741CrossRefPubMedPubMedCentral

30.

Wiesner S, Ogunjimi AA, Wang HR, Rotin D, Sicheri F, Wrana JL, Forman-Kay JD (2007) Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. Cell 130:651–662CrossRefPubMed

31.

Liu J, Wan L, Yuan Z, Zhang J, Guo J, Malumbres M, Zou W, Wei W (2016) Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner. Cell discov 2:15044CrossRefPubMedPubMedCentral

32.

Mund T, Graeb M, Mieszczanek J, Gammons M, Pelham HR, Bienz M (2015) Disinhibition of the HECT E3 ubiquitin ligase WWP2 by polymerized Dishevelled. Open Biol 5:150185CrossRefPubMedPubMedCentral

Title: WWP2 Is One Promising Novel Oncogene
Authors: Rui Zhang
Jianwu Zhang
Wei Luo
Zhuang Luo
Shaoqing Shi
Publication date: 01-04-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0506-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC

Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer

Candidate Tumor Suppressor Gene EAF2 is Mutated in Colorectal and Gastric Cancers

The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells

Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma – a Systematic Review with Meta Analysis

Early Skin Rash and Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer